Loading company…
Beijing-based METiS TechBio develops AI-driven nanomaterial platforms for drug delivery design and its own pipeline medicines.
Based in Beijing, China and established in 2020, METiS TechBio (Metis TechBio Co., Ltd.) designs and optimizes nanomaterial-based drug delivery systems using its AI-driven platforms. It licenses its technologies and provides formulation services to pharmaceutical companies and research institutions, and it also develops and out-licenses its own pipeline products. In May 2026 it raised HKD 2.11 billion in an IPO on the Hong Kong Exchanges and Clearing under the ticker 7666. It is at the Series D stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in